“Patient Preference for Calcipotriene 0.005% Betamethasone Dipropionate 0.064% Foam or Topical Suspension Vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study”. SKIN The Journal of Cutaneous Medicine 2, no. S1 (February 23, 2018): S10. Accessed May 2, 2026. https://skin.dermsquared.com/skin/article/view/279.